Drugs / enamel matrix proteins
enamel matrix proteins
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT04059458 | Oct 2019 → Nov 2023 | periodontal disorder | University of Oslo | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT04059445 | Oct 2019 → Nov 2023 | periodontal disorder | University of Oslo | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT03025204 | Feb 2016 → Apr 2018 | periodontitis, aggressive | University of Campinas, Brazil | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | enamel matrix proteins | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04059458 ↗ |
| Known as | EMD | “EMD is composed of different proteins, 90% of which are amelogenins, which has the capacity to induce processes involved in the regeneration of periodontal tissues” NCT03025204 ↗ |
| Known as | Straumann Emdogain | “Biphasic calcium phosphate (Straumann Bone Ceramic) + enamel matrix proteins (Straumann Emdogain)” NCT04059445 ↗1“enamel matrix proteins (Straumann Emdogain)” NCT04059458 ↗ |
| Modality | Protein / enzyme biologic | “EMD is composed of different proteins, 90% of which are amelogenins” NCT03025204 ↗ |